Αποτελέσματα Αναζήτησης
Tarceva in combination with gemcitabine is indicated for the treatment of patients with metastatic pancreatic cancer. When prescribing Tarceva, factors associated with prolonged survival should be taken into account.
15 Οκτ 2010 · In the placebo-controlled phase III SATURN study, maintenance erlotinib after first-line chemotherapy demonstrated significantly prolonged progression-free survival (PFS) and overall survival (OS) in the overall study population of patients with advanced non-small-cell lung cancer (NSCLC).
Use the date and time of ICH onset in Q01-Q02. If the date/ time of onset is unknown, use the date and time last seen normal SATURN Newsletter April 2021 · Issue 6
16 Φεβ 2022 · Trial protocol version and date: Version 3 22 November 2021. Recruitment will commence 25th April 2022. Recruitment to be completed by 31st May 2023
Tarceva® is approved in the European Union, United States and more than 100 other countries for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR-activating mutations. 2,3
The Sequential Tarceva in Unresectable NSCLC (SATURN) trial was designed to investigate the effectiveness of maintenance erlotinib treatment until the time of progression, with the goal of prolonging overall survival and delaying disease progression .
1 Αυγ 2005 · Since the BR.21 study was a placebo-controlled trial with the primary end point of survival, one has the opportunity to assess various factors as they relate to survival and other end points, including objective tumor response as determined by the Response Evaluation Criteria in Solid Tumors.
